Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma

<table>Comparison of the IFN-<i>γ</i>-positive and IL-4-negative (Th1) subset of CD4-positive T cells before and after treatment in the PR + SD group and PD group. There were no significant differences of Th1 cells between before treatment and after treatment in either group.</table>

Journal of Immunology Research

fig6

Figure 6

Figure 6: Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma 